|
US6346611B1
(en)
*
|
1990-06-11 |
2002-02-12 |
Gilead Sciences, Inc. |
High affinity TGfβ nucleic acid ligands and inhibitors
|
|
US6344321B1
(en)
*
|
1990-06-11 |
2002-02-05 |
Gilead Sciences, Inc. |
Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
|
|
US6395888B1
(en)
*
|
1996-02-01 |
2002-05-28 |
Gilead Sciences, Inc. |
High affinity nucleic acid ligands of complement system proteins
|
|
US6229002B1
(en)
|
1995-06-07 |
2001-05-08 |
Nexstar Pharmaceuticlas, Inc. |
Platelet derived growth factor (PDGF) nucleic acid ligand complexes
|
|
US6242246B1
(en)
|
1997-12-15 |
2001-06-05 |
Somalogic, Inc. |
Nucleic acid ligand diagnostic Biochip
|
|
AU2004242462B2
(en)
*
|
1999-07-29 |
2008-01-24 |
Gilead Sciences, Inc. |
Nucleic acid ligands to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor C-Met and to integrins
|
|
US7300922B2
(en)
|
2001-05-25 |
2007-11-27 |
Duke University |
Modulators of pharmacological agents
|
|
US7879991B2
(en)
*
|
2002-05-06 |
2011-02-01 |
Noxxon Pharma Ag |
CGRP binding nucleic acids
|
|
GB0213745D0
(en)
|
2002-06-14 |
2002-07-24 |
Univ Edinburgh |
Enzyme
|
|
JP2005533794A
(ja)
*
|
2002-06-18 |
2005-11-10 |
アーケミックス コーポレイション |
アプタマー−毒素分子およびこれを使用する方法
|
|
US20040249130A1
(en)
*
|
2002-06-18 |
2004-12-09 |
Martin Stanton |
Aptamer-toxin molecules and methods for using same
|
|
US8853376B2
(en)
|
2002-11-21 |
2014-10-07 |
Archemix Llc |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
US20040253243A1
(en)
*
|
2003-01-21 |
2004-12-16 |
David Epstein |
Aptamer therapeutics useful in ocular pharmacotherapy
|
|
US8039443B2
(en)
*
|
2002-11-21 |
2011-10-18 |
Archemix Corporation |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
US10100316B2
(en)
*
|
2002-11-21 |
2018-10-16 |
Archemix Llc |
Aptamers comprising CPG motifs
|
|
US20050124565A1
(en)
*
|
2002-11-21 |
2005-06-09 |
Diener John L. |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
EP2924119A1
(en)
|
2003-04-21 |
2015-09-30 |
Archemix LLC |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
US20040219663A1
(en)
*
|
2003-04-30 |
2004-11-04 |
Page Robert D. |
Biopolymer array fabrication using different drop deposition heads
|
|
US7727969B2
(en)
*
|
2003-06-06 |
2010-06-01 |
Massachusetts Institute Of Technology |
Controlled release nanoparticle having bound oligonucleotide for targeted delivery
|
|
NZ592039A
(en)
*
|
2003-08-27 |
2013-03-28 |
Ophthotech Corp |
Combination therapy for the treatment of ocular neovascular disorders
|
|
US7803931B2
(en)
|
2004-02-12 |
2010-09-28 |
Archemix Corp. |
Aptamer therapeutics useful in the treatment of complement-related disorders
|
|
PL3385384T3
(pl)
|
2004-02-12 |
2021-03-08 |
Archemix Llc |
Aptamerowe środki terapeutyczne użyteczne w leczeniu zaburzeń powiązanych z dopełniaczem
|
|
AU2005220910A1
(en)
*
|
2004-03-05 |
2005-09-22 |
Archemix Corp. |
Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
|
|
US20060193821A1
(en)
*
|
2004-03-05 |
2006-08-31 |
Diener John L |
Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
|
|
US20080214489A1
(en)
*
|
2004-04-19 |
2008-09-04 |
Anthony Dominic Keefe |
Aptamer-mediated intracellular delivery of oligonucleotides
|
|
US7579450B2
(en)
*
|
2004-04-26 |
2009-08-25 |
Archemix Corp. |
Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
|
|
US7566701B2
(en)
*
|
2004-09-07 |
2009-07-28 |
Archemix Corp. |
Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
|
|
JP2008512097A
(ja)
*
|
2004-09-07 |
2008-04-24 |
アーケミックス コーポレイション |
アプタマー医薬品化学
|
|
KR20070101227A
(ko)
|
2004-09-07 |
2007-10-16 |
아케믹스 코포레이션 |
폰 빌레브란트 인자에 대한 앱타머 및 이의 혈전증치료제로서의 용도
|
|
EP3034089A1
(en)
|
2004-11-02 |
2016-06-22 |
Archemix LLC |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
CA2601400A1
(en)
|
2005-03-19 |
2006-09-28 |
Medical Research Council |
Improvements in or relating to treatment and prevention of viral infections
|
|
US8101385B2
(en)
|
2005-06-30 |
2012-01-24 |
Archemix Corp. |
Materials and methods for the generation of transcripts comprising modified nucleotides
|
|
KR20080025181A
(ko)
|
2005-06-30 |
2008-03-19 |
아케믹스 코포레이션 |
완전 2'-변형된 핵산 전사체를 생성하기 위한 물질 및 방법
|
|
EP2368868A1
(en)
|
2005-10-28 |
2011-09-28 |
Praecis Pharmaceuticals Inc. |
Methods for identifying compounds of interest using encoded libraries
|
|
US7922000B2
(en)
*
|
2006-02-15 |
2011-04-12 |
Miraial Co., Ltd. |
Thin plate container with a stack of removable loading trays
|
|
KR101584468B1
(ko)
|
2006-03-08 |
2016-01-13 |
아케믹스 엘엘씨 |
안질환의 치료에 유용한 보체 결합 앱타머 및 항-ｃ5 제제
|
|
WO2008134077A1
(en)
*
|
2007-04-30 |
2008-11-06 |
Archemix Corp. |
Metabolic profile directed aptamer medicinal chemistry
|
|
US20090203766A1
(en)
*
|
2007-06-01 |
2009-08-13 |
Archemix Corp. |
vWF aptamer formulations and methods for use
|
|
US20080305157A1
(en)
*
|
2007-06-08 |
2008-12-11 |
University Of Maryland Office Of Technology Commercialization |
Encapsulation and separation of charged organic solutes inside catanionic vesicles
|
|
US20090233295A1
(en)
*
|
2008-01-29 |
2009-09-17 |
Elias Georges |
Trim59 directed diagnostics for neoplastic disease
|
|
US8207298B2
(en)
*
|
2008-05-01 |
2012-06-26 |
Archemix Corp. |
Methods of separating biopolymer conjugated molecules from unconjugated molecules
|
|
WO2010099139A2
(en)
|
2009-02-25 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Combination anti-cancer therapy
|
|
JP2012519282A
(ja)
|
2009-02-27 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
|
|
EP2401614A1
(en)
|
2009-02-27 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
GB0904957D0
(en)
|
2009-03-23 |
2009-05-06 |
Univ Erasmus Medical Ct |
Tumour gene profile
|
|
GB0915515D0
(en)
|
2009-09-04 |
2009-10-07 |
Ucl Business Plc |
Treatment of vasculoproliferative conditions
|
|
US8841429B2
(en)
*
|
2009-11-03 |
2014-09-23 |
Vivonics, Inc. |
Nucleic acid ligands against infectious prions
|
|
US8236570B2
(en)
|
2009-11-03 |
2012-08-07 |
Infoscitex |
Methods for identifying nucleic acid ligands
|
|
WO2011127933A1
(en)
|
2010-04-16 |
2011-10-20 |
Nuevolution A/S |
Bi-functional complexes and methods for making and using such complexes
|
|
GB201013573D0
(en)
|
2010-08-12 |
2010-09-29 |
Ucl Business Plc |
Treatment
|
|
GB201013785D0
(en)
|
2010-08-17 |
2010-09-29 |
Ucl Business Plc |
Treatment
|
|
GB201014026D0
(en)
|
2010-08-20 |
2010-10-06 |
Ucl Business Plc |
Treatment
|
|
WO2012038744A2
(en)
|
2010-09-22 |
2012-03-29 |
Genome Research Limited |
Detecting mutations
|
|
EP2702173A1
(en)
|
2011-04-25 |
2014-03-05 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
|
GB201120711D0
(en)
|
2011-12-01 |
2012-01-11 |
Univ Erasmus Medical Ct |
Method for classifying tumour cells
|
|
EP2802659A1
(en)
|
2012-01-10 |
2014-11-19 |
Noxxon Pharma AG |
Nucleic acids specifically binding cgrp
|
|
WO2013132267A1
(en)
|
2012-03-09 |
2013-09-12 |
Ucl Business Plc |
Treatment of cancer
|
|
CA2868096C
(en)
|
2012-03-28 |
2019-12-31 |
Somalogic, Inc. |
Aptamers to pdgf and vegf and their use in treating pdgf and vegf mediated conditions
|
|
GB201205739D0
(en)
|
2012-03-30 |
2012-05-16 |
Ucl Business Plc |
Treatment of acute inflammation in the respiratory tract
|
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
|
AU2014286996A1
(en)
|
2013-07-12 |
2016-01-07 |
Iveric Bio, Inc. |
Methods for treating or preventing ophthalmological conditions
|
|
US9695424B2
(en)
|
2013-09-09 |
2017-07-04 |
Somalogic, Inc. |
PDGF and VEGF aptamers having improved stability and their use in treating PDGF and VEGF mediated diseases and disorders
|
|
DE202014010499U1
(de)
|
2013-12-17 |
2015-10-20 |
Kymab Limited |
Targeting von humaner PCSK9 zur Cholesterinbehandlung
|
|
WO2015140722A1
(en)
|
2014-03-17 |
2015-09-24 |
Glaxosmithkline Intellectual Property Development Limited |
Aptamers for topical delivery
|
|
US9605266B2
(en)
|
2014-07-16 |
2017-03-28 |
City Of Hope |
Cell-specific internalizing RNA aptamers against human CCR5 and uses therefore
|
|
CN107249644A
(zh)
|
2014-10-15 |
2017-10-13 |
希望之城 |
针对转铁蛋白受体(TfR)的RNA适体
|
|
CN108290004A
(zh)
|
2015-11-18 |
2018-07-17 |
福尔密孔股份公司 |
含有vegf拮抗剂的预填充塑料注射器
|
|
WO2018218013A2
(en)
|
2017-05-24 |
2018-11-29 |
Sio2 Medical Products, Inc. |
Sterilizable pharmaceutical package for ophthalmic formulations
|
|
CA3005132A1
(en)
|
2015-11-18 |
2017-05-26 |
Sio2 Medical Products, Inc. |
Coated syringe for ophthalmic formulations containing a vegf antagonist
|
|
WO2017087798A1
(en)
|
2015-11-18 |
2017-05-26 |
Formycon Ag |
Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist
|
|
AU2017213103B2
(en)
|
2016-01-26 |
2022-08-11 |
Formycon Ag |
Liquid formulation of a VEGF antagonist
|
|
GB201704953D0
(en)
|
2017-03-28 |
2017-05-10 |
Imp Innovations Ltd |
Natural killer cells
|
|
WO2018215580A1
(en)
|
2017-05-24 |
2018-11-29 |
Formycon Ag |
Method for sterilizing prefilled plastic syringes containing a vegf antagonist
|
|
WO2018217995A1
(en)
|
2017-05-24 |
2018-11-29 |
Formycon Ag |
Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
|
|
RU2020112854A
(ru)
|
2017-11-30 |
2021-12-30 |
Арракис Терапьютикс, Инк. |
Фотозонды, связывающие нуклеиновые кислоты, и способы их применения
|
|
GB201804514D0
(en)
|
2018-03-21 |
2018-05-02 |
Ucl Business Plc |
Treatment of pyroptosis
|
|
GB201804515D0
(en)
|
2018-03-21 |
2018-05-02 |
Takayuki Takakondo |
Treatment of necroptosis
|
|
GB201804922D0
(en)
|
2018-03-27 |
2018-05-09 |
Ucl Business Plc |
Traatment
|
|
ES3018082T3
(en)
*
|
2019-06-25 |
2025-05-14 |
Actome Gmbh |
Method and kit for measuring of analytes in bi-component systems and uses thereof
|
|
GB202002711D0
(en)
|
2020-02-26 |
2020-04-08 |
Ucl Business Ltd |
Treatment
|
|
IL299215A
(en)
|
2020-06-25 |
2023-02-01 |
Medimmune Ltd |
Prevention of axonal damage through binding of an antibody to amyloid beta 1-42
|
|
US20240050389A1
(en)
|
2020-09-15 |
2024-02-15 |
Imperial College Innovations Limited |
Treatment of idiopathic pulmonary fibrosis
|
|
GB202017673D0
(en)
|
2020-11-09 |
2020-12-23 |
Imperial College Innovations Ltd |
Treatment of pulmonary arterial hypertensive
|
|
EP4475850A1
(en)
|
2022-02-09 |
2024-12-18 |
Imperial College Innovations Limited |
Treatment of telangiectasia
|
|
WO2024047368A1
(en)
|
2022-09-02 |
2024-03-07 |
Imperial College Innovations Limited |
Natural killer cells
|
|
GB202303784D0
(en)
|
2023-03-15 |
2023-04-26 |
Institute Of Cancer Res Royal Cancer Hospital |
Cancer treatment
|
|
WO2024261477A1
(en)
|
2023-06-20 |
2024-12-26 |
Yaqrit Limited |
Combination of tlr4 antagonist, ornithine and phenylacetate or phenylbutyrate
|